Clinical Trial Update: Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the pharmacokinetics, safety, and tolerability of intravenous secukinumab in patients with Giant Cell Arteritis or Polymyalgia Rheumati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Arteritis
• Polymyalgia Rheumatica

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Giant Cell Arteritis, Polymyalgia Rheumatica | Phase 1 | Status: COMPLETED